par Borg, Christophe;Thielemans, Kris M.;Le Cesne, Axel Le A.;Chung-Scott, Véronique;Lazar, Vladimir;Tchounkeu Kuigwa, Isabelle
;Crépineau, Florent;Lemoine, François;Bernard, Jacky;Fletcher, Jonhantan J.A.;Turhan, Ali;Terme, Magali;Blay, Jean Yves;Spatz, Alain;Emile, Jean-François;Heinrich, Michael Charles;Mécheri, Salah;Tursz, Thomas;Zitvogel, Laurence;Taieb, Julien;Ménard, Cédric;Flament, Caroline;Robert, Caroline;Maruyama, Koji
;Wakasugi, Hiro;Angevin, Eric
Référence The Journal of clinical investigation, 114, 3, page (379-388)
Publication Publié, 2004-08
;Crépineau, Florent;Lemoine, François;Bernard, Jacky;Fletcher, Jonhantan J.A.;Turhan, Ali;Terme, Magali;Blay, Jean Yves;Spatz, Alain;Emile, Jean-François;Heinrich, Michael Charles;Mécheri, Salah;Tursz, Thomas;Zitvogel, Laurence;Taieb, Julien;Ménard, Cédric;Flament, Caroline;Robert, Caroline;Maruyama, Koji
;Wakasugi, Hiro;Angevin, EricRéférence The Journal of clinical investigation, 114, 3, page (379-388)
Publication Publié, 2004-08
Article révisé par les pairs
| Résumé : | Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors. Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action. Here we show that Gleevec can act on host DCs to promote NK cell activation. DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT. Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner. Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response. These data point to a novel mode of antitumor action for Gleevec. |



